Identifying Significant Changes in Cerebrovascular Reactivity to Carbon Dioxide

O. Sobczyk, A.P. Crawley, J. Poubanc, K. Sam, D.M. Mandell, D.J. Mikulis, J. Duffin, and J.A. Fisher

ABSTRACT

BACKGROUND AND PURPOSE: Changes in cerebrovascular reactivity can be used to assess disease progression and response to therapy but require discrimination of pathology from normal test-to-test variability. Such variability is due to variations in methodology, technology, and physiology with time. With uniform test conditions, our aim was to determine the test-to-test variability of cerebrovascular reactivity in healthy subjects and in patients with known cerebrovascular disease.

MATERIALS AND METHODS: Cerebrovascular reactivity was the ratio of the blood oxygen level–dependent MR imaging response divided by the change in carbon dioxide stimulus. Two standardized cerebrovascular reactivity tests were conducted at 3T in 15 healthy men (36.7 ± 16.1 years of age) within a 4-month period and were coregistered into standard space to yield voxelwise mean cerebrovascular reactivity interval difference measures, composing a reference interval difference atlas. Cerebrovascular reactivity interval difference maps were prepared for 11 male patients. For each patient, the test-retest difference of each voxel was scored statistically as z-values of the corresponding voxel mean difference in the reference atlas and then color-coded and superimposed on the anatomic images to create cerebrovascular reactivity interval difference z-maps.

RESULTS: There were no significant test-to-test differences in cerebrovascular reactivity in either gray or white matter (mean gray matter, $P = .431$; mean white matter, $P = .857$; paired t test) in the healthy cohort. The patient cerebrovascular reactivity interval difference z-maps indicated regions where cerebrovascular reactivity increased or decreased and the probability that the changes were significant.

CONCLUSIONS: Accounting for normal test-to-test differences in cerebrovascular reactivity enables the assessment of significant changes in disease status (stability, progression, or regression) in patients with time.

ABBREVIATIONS: BOLD = blood oxygen level–dependent; CO₂ = carbon dioxide; CVR = cerebrovascular reactivity; EC-IC = extracranial to intracranial; ID = interval difference; PaCO₂ = arterial partial pressure of carbon dioxide; PetCO₂ = end-tidal partial pressure of carbon dioxide

Knowledge of the repeatability of any test is crucial for assessing not only the progress of a disease with time but also the effects of any therapeutic intervention. Cerebrovascular reactivity (CVR) is a test indicating the magnitude of CBF responses to a

vasoactive stimulus. Reductions in CVR have been shown to indicate an enhanced risk of stroke^{1–3} and reduced cognitive ability.⁴ There are currently a number of techniques for mapping CVR. We have found blood oxygen level–dependent (BOLD) MR imaging signal intensity during arterial partial pressure of carbon dioxide (PaCO₂) manipulation a reliable measure of CVR. Our CVR test is, in effect, a cerebrovascular “stress test,” in which occult regional limitations of hemodynamic reserve can be mapped using MR imaging of a stimulated global increase in CBF.^{5–7}

Clinical Aspects of CVR Maps

Clinically significant changes in CVR maps must be distinguishable from the normal variation in CVR due to equipment variability, artifacts such as patient movement, and normal day-to-day physiologic variability. If we consider a longitudinal study of a group of patients undergoing an intervention in which we wish to test the effectiveness of the intervention, performing a paired t test

Received July 22, 2015; accepted after revision October 23.

From the Institute of Medical Science (O.S., D.J.M., J.A.F.) and Department of Physiology (K.S., J.D., J.A.F.), University of Toronto, Toronto, Canada; and Joint Department of Medical Imaging and the Functional Neuroimaging Laboratory (A.P.C., J.P., K.S., D.M.M., D.J.M.) and Department of Anaesthesia and Pain Management (J.D., J.A.F.), University Health Network, Toronto, Canada.

J.A.F. is Chief Scientist and J.D. is Senior Scientist at Thornhill Research, a spin-off company from the University Health Network that developed the RespirAct. RespirAct is currently a noncommercial research tool assembled and made available by Thornhill Research to research institutions to enable CVR studies.

Please address correspondence to Olivia Sobczyk, MSc, Institute of Medical Science, Medical Sciences Building, One King's College Circle, University of Toronto, Toronto, ON, Canada, M5S 1A8; e-mail: o.pucci@mail.utoronto.ca

Indicates article with supplemental on-line table.

Indicates article with supplemental on-line photo.

<http://dx.doi.org/10.3174/ajnr.A4679>

would account for this background variability. In the case of a single patient whose improvement in CVR after an intervention is to be evaluated, we used a group of healthy control subjects to provide an equivalent statistical yardstick to test the significance of the measured change in CVR relative to the expected reproducibility of the test. To that end, we have standardized the PaCO₂ stimulus, a critical component for developing test-to-test reliability, MR imaging sequence parameters, and data analysis.^{8–10} Once this step has been performed, quantization of the unavoidable background variability in CVR “noise” can be ascertained. We hypothesize that the variations in CVR outside the range of these normal test-to-test changes will be attributable to pathophysiologic changes.

Study Aim

Therefore, our aim in this study was to develop and test a quantitative method for detecting significant within-subject changes in CVR with time. We created a voxelwise CVR test-to-test interval difference (ID) atlas for healthy subjects (CVR ID atlas). We used the SD of the CVR ID atlas to score the probability that the voxelwise differences between 2 CVR studies for a patient would exceed the normal variation (ie, *z* scores). We report on the use of this method to monitor the changes with time in CVR in 11 patients with intracranial steno-occlusive disease, most of whom had undergone revascularization procedures.

MATERIALS AND METHODS

Subjects and Ethics Approval

All studies conformed to the standards set by the latest revision of the Declaration of Helsinki and were approved by the Research Ethics Board of the University Health Network and Health Canada. All subjects gave written and informed consent. We recruited 15 healthy male subjects (mean age, 36.7 ± 16.1 years), with no history of neurologic or cardiovascular disease, who were non-smokers and were taking no medication, to generate the CVR ID atlas described below. They were asked not to engage in heavy exercise or drink caffeinated drinks on the day of the test. For the patient examples, we searched our database of the research ethics board–approved CVR studies in male subjects (to minimize hormonal effects on CVR) with chronic cerebrovascular disease (*n* = 11) who had undergone ≥2 CVR examinations.

Experimental Protocol

Hypercapnic Stimulus. Subjects were fitted with a facemask and connected to a sequential gas-delivery breathing circuit.¹¹ The patterns of end-tidal partial pressure of carbon dioxide (PetCO₂) and end-tidal partial pressure of oxygen were programmed into the automated gas blender (RespirAct; Thornhill Research, Toronto, Ontario, Canada) running the prospective gas-targeting algorithm of Slessarev et al.¹² A standardized step carbon dioxide (CO₂) stimulus sequence was implemented, consisting of the following: a baseline PetCO₂ of 40 mm Hg for 60 seconds, step to a hypercapnia of 50 mm Hg for 45 seconds, baseline for 90 seconds, hypercapnia for 120 seconds, and return to baseline for 60 seconds, all during isoxic normoxia. The implementation of prospective end-tidal gas control is described in greater detail by Slessarev et al.¹²

Table 1: Duration between CVR T1 scan and CVR T2 scan for each of the 15 healthy subjects in the ID CVR atlas

Subject No.	Time between T1 and T2
1	12 Weeks
2	4 Weeks
3	8 Weeks
4	2 Weeks
5	4 Weeks
6	8 Weeks
7	16 Weeks
8	2 Weeks
9	4 Weeks
10	4 Weeks
11	16 Weeks
12	2 Weeks
13	4 Weeks
14	12 Weeks
15	2 Weeks

Note:—T1 indicates time point 1; T2, time point 2.

MR Imaging Protocol and CVR Map Generation. MR imaging was performed with a 3T scanner (Signa; GE Healthcare, Milwaukee, Wisconsin) with an 8-channel phased array head coil and consisted of BOLD acquisitions using a gradient-echo pulse sequence with an echo-planar readout (TR/TE, 2000/30 ms; FOV, 24 × 24 cm; matrix size, 64 × 64; number of temporal frames, 254; 39 sections; section thickness, 5 mm; no intersection gap; and flip angle, 85°). The acquired MR imaging and PetCO₂ data were analyzed using Analysis of Functional NeuroImages software (AFNI; <http://afni.nimh.nih.gov/afni>).¹³ PetCO₂ data were time-shifted to the point of maximum correlation with the voxel showing the greatest positive BOLD signal change and were resampled at the TR. A linear, least-squares fit of the BOLD signal data series to the PetCO₂ data series was then performed on a voxel-by-voxel basis. BOLD images were then volume-registered and section-time corrected and coregistered to an axial 3D T1-weighted inversion recovery fast-spoiled gradient-recalled volume (TI/TR/TE, 450/8/3 ms; matrix size, 256 × 256; FOV, 22 × 22 cm; section thickness, 1 mm; and flip angle, 15°), which was acquired in the same imaging session.¹⁴ The slope of the linear relation between the BOLD signal and the PetCO₂ was color-coded to a spectrum of colors corresponding to the direction (positive or negative) and the magnitude of the correlation and overlaid on the corresponding structural scans to form CVR maps. All voxels with correlation coefficients between −0.125 and +0.125 were thresholded from the maps. All subjects and patients had <3 mm head movement in any direction during the scanning.

Analyzing the CVR Maps

Repeatability and Construction of the ID CVR Atlas. The 15 healthy subjects underwent 2 CVR measurements within a 4-month interval to mimic the times usually implemented for our patient CVR measurements pre- and postsurgical intervention (see Table 1 for between-study time intervals for the healthy subjects). Regional measures of CVR were obtained by segmenting the anatomic images into gray and white matter regions (SPM8 software; <http://www.fil.ion.ucl.ac.uk/spm/software/spm8>).

Construction of the CVR ID atlas proceeded by first coregistering all datasets into Montreal Neurological Institute standard

FIG 1. Comparison of CVR test 1 and CVR test 2 for gray matter (A) and white matter (B) for each of the 15 healthy subjects in the ID CVR atlas. There were no significant differences between tests (mean gray matter, $P = .431$; mean white matter, $P = .857$). The horizontal line in the box represents the median, the box represents the interquartile range (25% to 75%), and the whiskers represent the minimum and maximum values. T1 indicates time point session 1; T2, time point session 2.

Table 2: Mean (SEM) CVR between days and mean (SEM) CV for the gray and white matter regions of the healthy cohort

	Gray Matter	White Matter
Mean CVR ($\Delta\%$ BOLD/ Δ mm Hg)	0.228 (0.01)	0.117 (0.001)
Mean CV (%)	7.3 (1.33)	10.3 (2.19)

Note:—CV indicates coefficient of variation; SEM, standard error of the mean.

space (as defined by a T1-weighted Montreal Neurological Institute 152 standard template)^{15,16} and then by calculating a voxel-wise difference in CVR values between the 2 time points in each of the 15 subjects. From these difference maps, a spatial smoothing of full width at half maximum at 5 mm was applied to each voxel. The difference, mean, and SD over all subjects for each voxel (AFNI software)¹³ were calculated to produce the test-to-test CVR ID atlas. Comparisons with time for systematic differences in the CVR scans were evaluated by using paired Student t tests (significance, $P < .05$). Coefficients of variation for gray and white matter were evaluated as estimates of repeatability (SigmaPlot 12.5; Systat Software, San Jose, California).

CVR ID Z-Maps. After spatial normalization, test-to-test CVR differences were calculated for 10 male patients who underwent repeated CVR studies within a year (On-line Figure) and 1 male patient who underwent 5 CVR scans during a 3-year period, to produce their CVR ID maps. Because CVR changes little with age, we did not expect systematic differences in CVR in healthy subjects during the 4-month range of repeat studies, and indeed there were none ($P > .05$, paired Student t test). The differences that we saw were due to small errors in coregistration, partial voluming effects, and day-to-day physiologic changes in the subjects and in the hardware. Because they do not represent real systematic differences, the mean ID values would trend to zero with larger subject cohorts. The assumption of zero as the sample mean difference produces an unbiased, estimate of the SD. The z scores for these patients were calculated voxel-by-voxel as the difference between the patient CVR ID values and those of the reference cohort (ie, zero) divided by the CVR ID atlas SD. The resulting CVR ID z scores indicate the statistical probability that the magnitude of the CVR interval differences was outside the normal range. These calculated CVR ID z scores were then color-coded (On-line Figure and On-line Table¹⁰) and superimposed on the anatomic images to produce CVR ID

z -maps showing the distribution and statistical significance of changes in the patient CVRs with time.

RESULTS

Normal Repeatability

Figure 1 presents the distribution of the mean CVR values for both gray and white matter for each CVR test in the 15 control subjects. The overall mean CVR and coefficient of variation reproducibility measures for gray and white matter are presented in Table 2. On average, CVR measures were repeatable in both gray (coefficient of variation = 7.3%) and white matter (coefficient of variation = 10.3%), consistent with repeat-

ability measurements found in a previous study using the same CVR measurement method.¹⁷ The paired Student t test found no significant systematic differences between the CVR scans.

ID Atlas Characteristics

Figure 2 shows the spatial distribution of the CVR ID atlas mean and SD test-to-test differences. The mean differences (Fig 2A) are close to zero, with the highest differences located in the superior sagittal sinus. Mean CVR differences ($\pm$ standard error of the mean) in the ID atlas for gray matter were found to be 0.0057 ± 0.013 and 0.0047 ± 0.010 for white matter. Areas with the highest test-to-test differences in the CVR ID atlas (Fig 2B) were found in the cortex and regions with large veins.

ID Z-Map Examples

Figure 3 shows an application of the CVR ID atlas to assess changes in CVR with time in a healthy subject (not included in the CVR ID atlas).

Figure 4 shows the application of the CVR ID atlas to assess changes in CVR with time in a patient drawn from our data base (more patient examples are shown in the On-line Figure and On-line Table) with right extracranial to intracranial (EC-IC) bypass surgery. MR angiography shows complete right ICA occlusion and 90% left ICA stenosis preoperatively. Postoperatively, the patient continued to experience episodes of right hemisphere transient ischemic attacks. Their CVR map determined 1 month before surgery (Fig 4A) showed decreased CVR in the right hemisphere. CVR measured 4 months postoperatively (Fig 4B) shows improvement. The CVR ID z -map shows the distribution of the interval changes and indicates the probability that these changes are due to the normal test-to-test variability. The second follow-up CVR (Fig 4C) performed 3 months later shows regression of the CVR. Additional follow-up CVR studies (Fig 4D, -E) show that further changes in CVR were small and were mostly in the range of normal test-to-test variability. Figure 4F compares study A with study E, or the net change in CVR for the duration. It indicates that despite the regression of CVR in many areas following the operation, there are residual areas of increased CVR compared with the preoperative study.

FIG 2. Axial sections displaying the spatial distribution of the healthy cohort. A, The mean difference in CVR between the 2 CVR tests colored according to the scale shown on the right in percentage change of BOLD per millimeter-of-mercury change in PetCO₂. B, The SD of CVR differences. The color scale is on the right.

FIG 3. An axial section from the midbrain of a healthy subject's CVR maps measured 2 months apart. These CVR measurements show the spatial distribution of CVR values colored according to the scale shown (percentage change of BOLD per millimeter-of-mercury change in PetCO₂). The corresponding CVR ID z-map is shown on the right. The CVR ID z-map provides a perspective of the statistically normal differences in CVR with time.

DISCUSSION

Identifying Significant Changes with Time

In this article, we introduce a statistical analytic method for determining the voxelwise probability of a change in CVR between 2 scans: the CVR ID z-map. We minimized the test-to-test variability by standardizing what has previously been a major source of variability: the vasoactive stimulus.¹⁸ With most methods, the partial pressure of CO₂ of the hypercapnic stimulus varies widely.^{19,20} In this study, the stimulus was a precisely (± 2 mm Hg) repeatable change in PaCO₂. In a previous study, a patient's CVR scan was scored relative to a reference atlas to identify abnormal regions.⁸ That was a cross-sectional atlas designed to score the probability of CVR values differing from normal in a single patient; in contrast, the present CVR ID atlas provides the significance of CVR changes between ≥ 2 tests in a single patient with time. This capability of identifying changes between CVR tests is necessary for longitudinal studies, such as following the progress of disease and determining the effects of interventions.

Minimizing Variability in CVR Tests due to Variation in the Stimulus

Mapping cerebrovascular reactivity requires a vasoactive stimulus that applies to the entire brain. Infusing pharmacologic vasoactive agents such as acetazolamide results in a variability of blood levels with time and between subjects—even with standardized doses;

there is even a variation of the vasodilatory response to a given blood level (see Fierstra et al¹⁹ for a discussion). By contrast, using hypercapnia as the vasoactive stimulus²¹ can result in a more reliable response. The drawback of using hypercapnia as the vasoactive stimulus is the difficulty in repeatedly attaining a target PaCO₂. Infusing CO₂ into a face mask,²² inhaling a fixed concentration of CO₂,²³ or simply breath-holding²⁴ do not produce a reproducible stimulus and cannot even provide a reliable measure of the change in the PaCO₂.^{18,25} Therefore, we used a computer-controlled gas blender in this study to prospectively target a PetCO₂ that was equilibrated with PaCO₂.²⁶

This methodology enabled repeat administration of a standardized stimulus (from baseline PetCO₂ at 40.2 ± 1.1 mm Hg to 49.9 ± 1.5 mm Hg) and thereby minimized the stimulus variability in the atlas and individual patient CVR tests. Our test is focused on showing that the repeatability of a CVR test provides the potential for clinical application, regardless of the type of stimulus used. The greater the variability in the stimulus, the larger the SD is for each voxel in the ID atlas and the lower the sensitivity for detecting changes in CVR. The versatility in this approach is that each institution,

by standardizing its own acquisition sequences and vasoactive stimulus, can obtain its own custom reference atlas, and the z scores of the institution would be comparable with those of any other institution.²⁷

Accounting for Variability in CVR Tests due to Signal Variation

Despite the precise designation of the MR imaging sequences and data analysis, there are nevertheless technical causes for variation in the CVR measurements. During acquisition, the BOLD signal can be affected by drift that has no consistent pattern or direction with time. In addition, there is day-to-day physiologic variability in vascular reactivity. The CVR ID atlas incorporates these variabilities so that CVR ID z-maps provide a confidence interval for identifying changes other than those attributable to these factors. The choice of thresholds for test-to-test difference determines the balance between sensitivity and specificity.

Change in CVR with Time in Patients with Cerebrovascular Disease

In the patients we studied (On-line Figure and On-line Table), the symptoms were mild and transient. In contrast, the obstructions to the vessels as seen on angiography were severe. The CVR mea-

FIG 4. Longitudinal changes in CVR for a 56-year-old man with bilateral ICA stenosis who underwent right EC-IC bypass. Axial sections of CVR maps (*upper row*) with the color scale are shown on the right (percentage change of BOLD per millimeter-of-mercury change in PetCO_2). A, CVR map 1 month prior to surgery; B, CVR measured 4 months postoperatively; C, second follow-up CVR measured 8 months postoperatively; D and E, additional follow-up CVR maps measured 18 and 35 months postoperatively. Their corresponding CVR ID z-maps are found in the *second and third rows*, as indicated by the *brackets*. F is an ID z-map that compares study A with study E, or the net change in CVR for the entire duration. See text for interpretations.

measurements were more physiologic in nature, reflecting the balance of blood flow resulting from the establishment of spontaneously developing and surgically established collateral blood flow. In these patients, the CVR ID z-maps indicated the significant changes in CVR with time, adding to the assessment of the success of surgical interventions. This ability is well-illustrated in the patient shown in Fig 4. In this patient, bypass revascularization surgery transiently improved CVR, but not to normal values. Thereafter, however, the CVR ID z-maps showed the degree and extent to which CVR progressively declined to a stable level at the final follow-up scan. The patient continuing to be symptomatic is also consistent with the CVR scans.

Limitations

Accurate measurement of CBF in advanced cerebrovascular disease is difficult. PET remains the criterion standard, and current MR imaging vendor implementations of arterial spin-labeling have yet to be proved/validated for clinical use.²⁸ The use of BOLD as a surrogate measure of CBF is common and has been shown to correlate well with other modalities, including FAIR arterial spin-labeling²⁹ (also see Duffin et al⁹ and Tancredi et al³⁰ for discussions). Nevertheless, the relationship between blood flow and BOLD is nonlinear.^{31,32} The atlas approach helps to mitigate this issue. In this article, the z scores account for the limitations of BOLD reflecting CBF because this measure of CBF was used in both the patient studies and the atlas. As improved methods of measuring CBF become available, the same analysis methodology can also be applied.

Within-subject variability of CVR may differ more with age and sex than in the men in our reference cohort.³³ In this study, we examined male subjects and used only men for our reference

atlas. Nevertheless, we note that the between-day differences in CVR in women studied with a methodology similar to ours found no significant interval differences.¹⁷ Our reference CVR ID atlas was not selected for a specific age group (mean age, 36.7 ± 16.1), and neither was our patient cohort. The effect of age on CVR is unclear. Some studies found reductions in CVR^{34,35}; we and others found no correlation between age and CVR.^{27,36} However, the question is not whether age is a factor in CVR but whether age is a factor in test-retest differences obtained within a matter of a few months. There is no reason to suppose that interval differences in healthy subjects differ greatly with age.

Another limitation to the sensitivity of this study is the variation in the time differences between measurements. Test-to-test differences due to the variable duration between tests are probably of the same order of magnitude as those due to discrepancies in sex, comorbidities, or other anthropomorphic factors. Such unaccounted for discrepancies will

further reduce the sensitivity and increase specificity of the atlas by reducing the ID z-values.

In our CVR ID z-map approach, it is assumed that the range of test-to-test variability in CVR found in the abnormal areas of our patient group is the same as that in healthy tissue. We therefore assume that any changes in the abnormal tissue CVR with time due to a pathological process will be greater than changes in normal tissue, ensuring the ability of the CVR ID z-maps to distinguish true pathologic changes in abnormal areas. Nevertheless, further investigation may be required to determine the “normal” variability in abnormal areas. For this measurement, patient scans should be repeated within a short time (eg, <1 week), within which no substantial change would be expected in, for example, patients who are stable and not candidates for revascularization. Their CVR ID z-maps would reflect the normal variability in abnormal areas. Such measurements are shown in Fig 4, where CVR ID z-maps show no changes between C and D, and D and E.

Finally, a key confounding factor that affects CVR interpretation is blood pressure.³⁷ However, we were not able to measure blood pressure due to the constraints imposed by the MR imaging environment on this measurement. Accurate frequent blood pressure sampling in the MR imaging environment would aid in assessing the sensitivity of the CVR ID z scoring in the future.

CONCLUSIONS

CVR ID z-maps are a secondary analysis of CVR maps that provides a statistical approach to separate test-to-test differences due to technical and physiologic changes with time from those due to changes in the underlying pathophysiology, informing the clinical assessment of disease activity and the response to treatment. The patients we present underwent considerable

changes in CVR. The lower the likelihood that these changes represent test-to-test variability, the more likely they are to represent underlying pathophysiology, despite few overt changes in symptoms. We therefore suggest that the advanced analysis of the CVR data by using CVR ID z-maps introduced in this article can improve assessment of longitudinal subclinical pathophysiologic changes that are difficult to gauge by using angiography and CVR maps alone.

ACKNOWLEDGMENTS

The authors thank Toronto Western Hospital MR imaging technologist Eugen Hlasny for his help in acquiring the MR imaging data and clinical coordinator Abby Skanda for her help with study organization.

Disclosures: Olivia Sobczyk—UNRELATED: Consultancy/Employment: I am a consultant (part-time) of Thornhill Research, whose parent company owns intellectual property on the RespirAct device used in the study. James Duffin—UNRELATED: Employment, Patents (planned, pending or issued), Stock/Stock Options: Thornhill Research. Joseph A. Fisher—RELATED: Consulting Fee or Honorarium: The device that was used to control blood gases in the CVR experiments in this study is a custom prototype built by Thornhill Research, which is a spin-off of the University Health Network. I am also one of the inventors of this device and the chief scientist at Thornhill Research.

REFERENCES

- Markus H, Cullinane M. Severely impaired cerebrovascular reactivity predicts stroke and TIA risk in patients with carotid artery stenosis and occlusion. *Brain* 2001;124:457–67 CrossRef Medline
- Ogasawara K, Ogawa A, Yoshimoto T. Cerebrovascular reactivity to acetazolamide and outcome in patients with symptomatic internal carotid or middle cerebral artery occlusion: a xenon-133 single-photon emission computed tomography study. *Stroke* 2002;33:1857–62 CrossRef Medline
- Sasoh M, Ogasawara K, Kuroda K, et al. Effects of EC-IC bypass surgery on cognitive impairment in patients with hemodynamic cerebral ischemia. *Surg Neurol* 2003;59:455–60; discussion 460–63 CrossRef Medline
- Silvestrini M, Viticchi G, Falsetti L, et al. The role of carotid atherosclerosis in Alzheimer's disease progression. *J Alzheimers Dis* 2011;25:719–26 CrossRef Medline
- Han JS, Mandell DM, Poubanc J, et al. BOLD-MRI cerebrovascular reactivity findings in cocaine-induced cerebral vasculitis. *Nat Clin Pract Neurol* 2008;4:628–32 CrossRef Medline
- Fierstra J, Poubanc J, Han JS, et al. Steal physiology is spatially associated with cortical thinning. *J Neurol Neurosurg Psychiatry* 2010;81:290–93 CrossRef Medline
- Mandell DM, Han JS, Poubanc J, et al. Quantitative measurement of cerebrovascular reactivity by blood oxygen level-dependent MR imaging in patients with intracranial stenosis: preoperative cerebrovascular reactivity predicts the effect of extracranial-intracranial bypass surgery. *AJNR Am J Neuroradiol* 2011;32:721–27 CrossRef Medline
- Sobczyk O, Battisti-Charbonney A, Fierstra J, et al. A conceptual model for CO₂-induced redistribution of cerebral blood flow with experimental confirmation using BOLD MRI. *Neuroimage* 2014;92:56–68 CrossRef Medline
- Duffin J, Sobczyk O, Crawley AP, et al. The dynamics of cerebrovascular reactivity shown with transfer function analysis. *Neuroimage* 2015;114:207–16 CrossRef Medline
- Poubanc J, Crawley AP, Sobczyk O, et al. Measuring cerebrovascular reactivity: the dynamic response to a step hypercapnic stimulus. *J Cereb Blood Flow Metab* 2015;35:1746–56 CrossRef Medline
- Sommer LZ, Iscoe S, Robicsek A, et al. A simple breathing circuit minimizing changes in alveolar ventilation during hyperpnoea. *Eur Respir J* 1998;12:698–701 CrossRef Medline
- Slessarev M, Han J, Mardimae A, et al. Prospective targeting and control of end-tidal CO₂ and O₂ concentrations. *J Physiol* 2007;581:1207–19 CrossRef Medline
- Cox RW. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. *Comput Biomed Res* 1996;29:162–73 CrossRef Medline
- Saad ZS, Glen DR, Chen G, et al. A new method for improving functional-to-structural MRI alignment using local Pearson correlation. *Neuroimage* 2009;44:839–48 CrossRef Medline
- Ashburner J, Friston K. Multimodal image coregistration and partitioning: a unified framework. *Neuroimage* 1997;6:209–17 CrossRef Medline
- Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. *Hum Brain Mapp* 1999;7:254–66 Medline
- Kassner A, Winter JD, Poubanc J, et al. Blood-oxygen level dependent MRI measures of cerebrovascular reactivity using a controlled respiratory challenge: reproducibility and gender differences. *J Magn Reson Imaging* 2010;31:298–304 CrossRef Medline
- Mark CI, Slessarev M, Ito S, et al. Precise control of end-tidal carbon dioxide and oxygen improves BOLD and ASL cerebrovascular reactivity measures. *Magn Reson Med* 2010;64:749–56 CrossRef Medline
- Fierstra J, Sobczyk O, Battisti-Charbonney A, et al. Measuring cerebrovascular reactivity: what stimulus to use? *J Physiol* 2013;591:5809–21 CrossRef Medline
- Tancredi FB, Hoge RD. Comparison of cerebral vascular reactivity measures obtained using breath-holding and CO₂ inhalation. *J Cereb Blood Flow Metab* 2013;33:1066–74 CrossRef Medline
- Kety SS, Schmidt CF. The effects of altered arterial tension of carbon dioxide and oxygen on cerebral blood flow and cerebral oxygen consumption of normal young men. *J Clin Invest* 1948;27:484–92 CrossRef Medline
- Markus HS, Harrison MJ. Estimation of cerebrovascular reactivity using transcranial Doppler, including the use of breath-holding as the vasodilatory stimulus. *Stroke* 1992;23:668–73 CrossRef Medline
- van der Zande FH, Hofman PA, Backes WH. Mapping hypercapnia-induced cerebrovascular reactivity using BOLD MRI. *Neuroradiology* 2005;47:114–20 CrossRef Medline
- Silvestrini M, Vernieri F, Troisi E, et al. Cerebrovascular reactivity in carotid artery occlusion: possible implications for surgical management of selected groups of patients. *Acta Neurol Scand* 1999;99:187–91 CrossRef Medline
- Prisman E, Slessarev M, Azami T, et al. Modified oxygen mask to induce target levels of hyperoxia and hypercarbia during radiotherapy: a more effective alternative to carbogen. *Int J Radiat Biol* 2007;83:457–62 CrossRef Medline
- Ito S, Mardimae A, Han J, et al. Non-invasive prospective targeting of arterial P(CO₂) in subjects at rest. *J Physiol* 2008;586:3675–82 CrossRef Medline
- Sobczyk O, Battisti-Charbonney A, Poubanc J, et al. Assessing cerebrovascular reactivity abnormality by comparison to a reference atlas. *J Cereb Blood Flow Metab* 2015;35:213–20 CrossRef Medline
- Grade M, Hernandez Tamames JA, Pizzini FB, et al. A neuroradiologist's guide to arterial spin labeling MRI in clinical practice. *Neuroradiology* 2015;57:1181–202 CrossRef Medline
- Mandell DM, Han JS, Poubanc J, et al. Mapping cerebrovascular reactivity using blood oxygen level-dependent MRI in patients with arterial steno-occlusive disease: comparison with arterial spin labeling MRI. *Stroke* 2008;39:2021–28 CrossRef Medline
- Tancredi FB, Lajoie I, Hoge RD. Test-retest reliability of cerebral blood flow and blood oxygenation level-dependent responses to hypercapnia and hyperoxia using dual-echo pseudo-continuous arterial spin labeling and step changes in the fractional composition of inspired gases. *J Magn Reson Imaging* 2015;42:1144–57 CrossRef Medline
- Davis TL, Kwong KK, Weisskoff RM, et al. Calibrated functional MRI: mapping the dynamics of oxidative metabolism. *Proc Natl Acad Sci U S A* 1998;95:1834–39 CrossRef Medline
- Hoge RD, Atkinson J, Gill B, et al. Investigation of BOLD signal

- dependence on cerebral blood flow and oxygen consumption: the deoxyhemoglobin dilution model. *Magn Reson Med* 1999;42:849–63 [Medline](#)
33. Kastrup A, Thomas C, Hartmann C, et al. Sex dependency of cerebrovascular CO₂ reactivity in normal subjects. *Stroke* 1997;28:2353–56 [CrossRef](#) [Medline](#)
 34. Flück D, Beaudin AE, Steinback CD, et al. Effects of aging on the association between cerebrovascular responses to visual stimulation, hypercapnia and arterial stiffness. *Front Physiol* 2014;5:49 [CrossRef](#) [Medline](#)
 35. Mark CI, Mazerolle EL, Chen JJ. Metabolic and vascular origins of the BOLD effect: implications for imaging pathology and resting-state brain function. *J Magn Reson Imaging* 2015;42:231–46 [CrossRef](#) [Medline](#)
 36. Schwertfeger N, Neu P, Schlattmann P, et al. Cerebrovascular reactivity over time course in healthy subjects. *J Neurol Sci* 2006;249:135–39 [CrossRef](#) [Medline](#)
 37. Regan RE, Fisher JA, Duffin J. Factors affecting the determination of cerebrovascular reactivity. *Brain Behav* 2014;4:775–88 [CrossRef](#) [Medline](#)